scispace - formally typeset
I

Isabel Lastres-Becker

Researcher at Spanish National Research Council

Publications -  61
Citations -  5581

Isabel Lastres-Becker is an academic researcher from Spanish National Research Council. The author has contributed to research in topics: Cannabinoid receptor & Neurodegeneration. The author has an hindex of 34, co-authored 57 publications receiving 4210 citations. Previous affiliations of Isabel Lastres-Becker include Centre national de la recherche scientifique & Goethe University Frankfurt.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

Daniel J. Klionsky, +2983 more
- 08 Feb 2021 - 
TL;DR: In this article, the authors present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes.
Journal ArticleDOI

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.

TL;DR: The results support the view of a potential neuroprotective action of cannabinoids against the in vivo and in vitro toxicity of 6-hydroxydopamine, which might be relevant to Parkinson's disease (PD).
Journal ArticleDOI

Transcription factors NRF2 and NF-κB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation.

TL;DR: A new mechanism of modulation of RAC1 inflammatory pathway is demonstrated through a cross-talk between NF-κB and NRF2, the master regulator of the anti-oxidant response.
Journal ArticleDOI

Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration.

TL;DR: Analysis of cannabinoid CB1 receptor mRNA expression and binding capacity revealed that cortical subfields exhibited an up‐regulation of these parameters following mild concussive head trauma and exposure to NMDA receptor blockade, which may suggest that mild to moderate brain injury may trigger elevated endocannabinoid activity via concomitant increase of anandamide levels, but not 2‐AG, andCB1 receptor density.